The integrated site featuring state-of-the-art single-use equipment and on-site regulatory, quality and technical experts, will provide global supply of commercial drug substances, including mAbs and other recombinant protein.

The new integrated 2,700 m² facility, which Merck said is designed to operate at the highest levels of efficiency, will provide global supply of commercial drug substances, including mAbs and other recombinant proteins.

With the ability to rapidly pivot from 200 to 2,000 liters of drug substance, Martillac also has two 2,000-liter bioreactors in one manufacturing suite to increase capacity and flexibility.

Leveraging state-of-the-art technology and a proven quality system allows for the streamlining and acceleration of the commercialization process by eliminating the need for tech transfer and scale-up between clinical and commercial stages, the pharmaceuticals, chemicals and life sciences group said.

At its sites throughout Europe, the US, and Asia, Millipore’s CTDMO services span pre-clinical to commercial phases, including testing across multiple modalities encompassing mAbs, highly potent active pharmaceutical ingredients, antibody-drug conjugates, viral vector therapies, mRNA and lipid nanoparticle formulation. This includes hardware and software, single-use consumables, and raw materials.

Author: Dede Williams, Freelance Journalist